4WEALTH Advisors Inc. Takes Position in Johnson & Johnson (NYSE:JNJ)

4WEALTH Advisors Inc. bought a new position in Johnson & Johnson (NYSE:JNJ - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 11,133 shares of the company's stock, valued at approximately $1,610,000. Johnson & Johnson makes up 1.6% of 4WEALTH Advisors Inc.'s investment portfolio, making the stock its 12th largest holding.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. IFS Advisors LLC boosted its stake in shares of Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after buying an additional 100 shares during the last quarter. WealthTrak Capital Management LLC bought a new position in Johnson & Johnson in the 4th quarter valued at $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at $29,000. Bay Harbor Wealth Management LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter worth $32,000. Finally, Conquis Financial LLC bought a new position in Johnson & Johnson during the fourth quarter valued at about $33,000. Institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 25th. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price target for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Argus raised Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Leerink Partners decreased their price objective on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a research note on Thursday, January 23rd. Finally, Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $171.82.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of the business's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $154.42 on Friday. The company has a market capitalization of $371.54 billion, a P/E ratio of 23.22, a P/E/G ratio of 2.56 and a beta of 0.49. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The business's 50 day moving average is $159.05 and its two-hundred day moving average is $154.73. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.37%. Johnson & Johnson's dividend payout ratio is presently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.